Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.

Aziz, Atiqullah; Dobruch, Jakub; Hendricksen, Kees; Kluth, Luis A; Necchi, Andrea; Noon, Aidan; Rink, Michael; Roghmann, Florian; Seiler, Roland; Gontero, Paolo; Kassouf, Wassim; Shariat, Shahrokh F; Xylinas, Evanguelos (2017). Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World journal of urology, 35(9), pp. 1401-1407. Springer 10.1007/s00345-016-1995-z

[img] Text
Seiler_World J Urol_Perioperative chemo.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (420kB) | Request a copy

PURPOSE To evaluate the role of neoadjuvant (NAC) and adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). METHODS A comprehensive review of the current literature was performed searching for all studies investigating NAC and AC in UTUC in MEDLINE and https://clinicaltrials.gov , prior to April 2016. The following keywords were used: "ureteral neoplasms," "urothelium," "ureter," "upper tract urothelial," "chemotherapy," "adjuvant," "neoadjuvant" and relevant variants. RESULTS No randomized trials investigated the role of AC or NAC for UTUC. There was one prospective study with n = 36 patients investigating AC with carboplatin-paclitaxel. We included 14 retrospective studies (four in the NAC and ten in the AC setting), with a total of 694 patients receiving cisplatin-based or non-cisplatin-based AC after RNU and 1437 patients undergoing RNU alone. We found that the current literature, mainly based on retrospective studies, suggests significant overall and cancer-specific survival benefits for AC in UTUC. NAC appears promising, with favorable pathologic response rates up to 14%. CONCLUSIONS Evidence is scarce for both NAC and AC use in UTUC. This comprehensive review suggests promising response rates for NAC and a survival benefit for patients treated with AC. Prospective randomized trials are needed to establish the role of AC and NAC in UTUC.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Seiler, Roland

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0724-4983

Publisher:

Springer

Language:

English

Submitter:

Laetitia Hayoz

Date Deposited:

07 Mar 2018 17:34

Last Modified:

25 Oct 2019 07:42

Publisher DOI:

10.1007/s00345-016-1995-z

PubMed ID:

28074261

Uncontrolled Keywords:

Adjuvant chemotherapy Neoadjuvant chemotherapy Radical nephroureterectomy Upper urinary tract tumors Urothelial carcinoma

BORIS DOI:

10.7892/boris.108739

URI:

https://boris.unibe.ch/id/eprint/108739

Actions (login required)

Edit item Edit item
Provide Feedback